10-Q: Amylyx Pharmaceuticals Reports Q2 2024 Results, Focuses on Pipeline After RELYVRIO Discontinuation

Amylyx Pharmaceuticals reported its Q2 2024 results, highlighting a strategic shift towards its pipeline programs following the discontinuation of RELYVRIO/ALBRIOZA.

Summary

• Amylyx Pharmaceuticals reported a net loss of $72.7 million for the three months ended June 30, 2024, and a net loss of $191.5 million for the six months ended June 30, 2024.
• The company's product revenue was significantly impacted by the voluntary discontinuation of RELYVRIO/ALBRIOZA, resulting in a net product revenue of negative $1.023 million for the quarter and $87.6 million for the six months ended June 30, 2024.
• Operating expenses totaled $75.3 million for the quarter and $286 million for the six months ended June 30, 2024, including $22.9 million in restructuring expenses.
• Research and development expenses were $23.3 million for the quarter and $60 million for the six months ended June 30, 2024, with a focus on AMX0035 for PSP and Wolfram syndrome, and AMX0114 for ALS.
• The company completed the acquisition of avexitide for $35.1 million on July 9, 2024, and plans to begin a Phase 3 program for avexitide in post-bariatric hypoglycemia in the first quarter of 2025.
• Amylyx is planning to wind down the Open Label Extension for RELYVRIO/ALBRIOZA by the end of 2024, but will continue to collect survival data from the PHOENIX trial.
• As of June 30, 2024, Amylyx had cash, cash equivalents, and short-term investments of $309.8 million, which they believe will be sufficient to meet their operating and capital expenditure requirements for at least one year.

Sentiment

Score: 4

Explanation: The document reflects a significant setback with the discontinuation of RELYVRIO/ALBRIOZA and a large net loss, but also shows a strategic pivot towards a pipeline with potential. The sentiment is cautiously optimistic, but the near-term outlook is challenging.

Positives

• The acquisition of avexitide expands Amylyx's pipeline into the endocrine and metabolic space, with a Phase 3 program planned for PBH.
• The HELIOS trial of AMX0035 for Wolfram syndrome showed promising interim results, indicating a potential treatment option for this rare disease.
• The company is advancing AMX0114, a potent antisense oligonucleotide, for ALS, with a clinical trial planned for the second half of 2024.
• Amylyx has a substantial cash position of $309.8 million, which is expected to fund operations for at least one year.

Negatives

• The voluntary discontinuation of RELYVRIO/ALBRIOZA resulted in a significant loss of product revenue and substantial inventory write-downs.
• The company reported a net loss of $191.5 million for the six months ended June 30, 2024.
• The restructuring plan included a 70% reduction in workforce, which may impact the company's operations and morale.
• The Phase 3 PHOENIX trial for RELYVRIO/ALBRIOZA in ALS failed to meet its primary and secondary endpoints, leading to the product's withdrawal from the market.

Risks

• The company's future success depends heavily on the successful development and commercialization of AMX0035 for indications other than ALS, avexitide, and AMX0114.
• Clinical trials for AMX0035, avexitide, and AMX0114 may not be successful, and regulatory approvals may be delayed or denied.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or supply issues.
• The market for AMX0035 in Wolfram syndrome and PSP, and for avexitide in PBH and congenital HI, may be smaller than expected.
• The company may require substantial additional funding in the future to meet its financial needs and pursue its business objectives.
• The company is subject to risks associated with economic uncertainty, geopolitical instability, and ongoing military conflicts.

Future Outlook

Amylyx plans to focus on its pipeline programs, including AMX0035 for PSP and Wolfram syndrome, AMX0114 for ALS, and avexitide for hyperinsulinemic hypoglycemia. The company expects to begin a Phase 3 program for avexitide in PBH in the first quarter of 2025 and anticipates data from an interim analysis of the ORION study in mid-2025. They believe their current cash position will fund operations for at least one year.

Management Comments

• The company is committed to the discovery and development of new treatment options for communities with high unmet needs.
• Amylyx is focused on advancing avexitide, AMX0035, and AMX0114 through clinical development.
• The company believes that its existing cash, cash equivalents, and short-term investments will be sufficient to meet its anticipated operating and capital expenditure requirements for at least twelve months after the date of this report.

Industry Context

This announcement reflects a significant shift in strategy for Amylyx, moving away from commercialization of RELYVRIO/ALBRIOZA and focusing on its pipeline. This is not uncommon in the biotech industry, where companies often pivot based on clinical trial results and market dynamics. The acquisition of avexitide also signals a diversification of the company's therapeutic focus.

Comparison to Industry Standards

• The discontinuation of RELYVRIO/ALBRIOZA after a failed Phase 3 trial is a common occurrence in the pharmaceutical industry, highlighting the high risk and uncertainty associated with drug development.
• The restructuring plan, including a significant workforce reduction, is a typical response to a major setback in a company's lead program, as seen in other biotech companies facing similar challenges.
• The acquisition of avexitide is a strategic move to diversify the pipeline and leverage existing assets, a common practice among biotech companies seeking to expand their therapeutic focus.
• The focus on rare diseases like Wolfram syndrome and PSP aligns with a growing trend in the pharmaceutical industry to address unmet medical needs in niche markets.
• The company's cash position of $309.8 million is relatively strong compared to other clinical-stage biotech companies, providing a runway for continued development efforts.

Management Changes

Legal Proceedings

• A putative class action lawsuit was filed against the company and certain of its current and former officers, alleging materially false and misleading statements related to the commercial results and prospects for RELYVRIO. The case has been transferred to the United States District Court for the District of Massachusetts.

Stakeholder Impact

• Shareholders will experience a significant decrease in value due to the discontinuation of RELYVRIO/ALBRIOZA and the resulting financial losses.
• Employees have been significantly impacted by the restructuring plan, with a 70% reduction in workforce.
• Patients with ALS will no longer have access to RELYVRIO/ALBRIOZA, but the company will continue to collect survival data from the PHOENIX trial.
• Patients with Wolfram syndrome and PSP may benefit from the ongoing development of AMX0035.
• Patients with hyperinsulinemic hypoglycemia may benefit from the development of avexitide.

Next Steps

• Initiate a Phase 3 program for avexitide in post-bariatric hypoglycemia in the first quarter of 2025.
• Present topline data from the HELIOS trial of AMX0035 for Wolfram syndrome at a medical meeting this fall.
• Continue the ORION trial of AMX0035 for PSP, with an interim analysis expected in mid-2025.
• Initiate a multiple ascending dose clinical trial of AMX0114 in people living with ALS in the second half of 2024.
• Wind down the Open Label Extension for RELYVRIO/ALBRIOZA by the end of 2024.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMX0035, avexitide, AMX0114, RELYVRIO, ALBRIOZA, ALS, PSP, Wolfram syndrome, hyperinsulinemic hypoglycemia, post-bariatric hypoglycemia, clinical trials, biotechnology, pharmaceuticals, restructuring, acquisition